Close Menu

private financing

The funds will support Curetis' R&D efforts, which include partnering its Unyvero A30 RQ mid-plex diagnostics system for verification and validation testing.

The company said it will use the funding in part to accelerate the development of products based on its proprietary de novo nucleic acid synthesis technology.

The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.

The La Jolla, California-based firm plans to use the funds to accelerate research partnerships around its LunaDNA genomic data sharing platform.

BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.

The Boston-based company offers a DNA test for dogs that it said can provide information on breed, ancestry, health, and disease risk.

Sano will use the funding to support its research platform, through which individuals can submit their medical history and genetic data for research studies.

The company — which is based in the US and trades on the Toronto Stock Exchange — announced plans for the private placement earlier this month.

The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.

The company — a spinout of the New York Genome Center — said it will use the funding in part to develop its technologies for new applications in agriculture.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.